Remove Containment Remove Doctors Remove Gene Remove Protein
article thumbnail

The democratisation of cell and gene therapy

Drug Discovery World

Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. So yes, you’ve got protein, but it’s not going to transfect or infect.” That’s not the case in CGT.”

article thumbnail

Suppressing the spread of tumors

The Pharma Data

They took a close look at the role of a protein called MFSD1 – the mammalian relative of a protein they had previously identified as affecting cell migration in fruit flies. Therefore, first author Marko Roblek from the Siekhaus group created mouse cancer cells lacking the protein. Protein prevents detachment.

Protein 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New CRISPR-Based Rapid COVID-19 Test Can Detect SARS-CoV-2 Variants

XTalks

Moreover, studies show that saliva samples can contain a marginally higher SARS-CoV-2 viral load compared with nasopharyngeal samples (shown in a study involving hospitalized patients), and that the virus can be detected in saliva for a greater number of days post-infection. A porous membrane was engineered to capture RNA on its surface.

RNA 105
article thumbnail

Women in Science Who Have Paved the Way Forward in Genetics

XTalks

After several such Nobel Prize snubs for female scientists, 2020 saw the Nobel Prize in Chemistry go to a female scientist duo for the first time for their revolutionary discovery of the CRISPR-Cas9 gene editing system. She was actually able to use the research for her doctoral thesis, graduating with a doctorate from Cambridge in 1945.

Genetics 119
article thumbnail

Sickle Cell Disease: The Importance of Amplifying Patient Voices

Advarra

Red blood cells contain hemoglobin, a protein that carries oxygen. These are reasons for biotech organizations to renew a focus on improving diversity in clinical research while bringing more sickle cell gene therapies to market. A visit to a podiatrist and family doctor yielded less than satisfactory diagnoses.

article thumbnail

Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer

The Pharma Data

TIGIT and PD-L1 are proteins that play a role in suppression of the immune system. Tiragolumab is a monoclonal antibody designed to bind with TIGIT, a protein receptor on immune cells. Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Dual blockade of the TIGIT and PD-L1 pathways.

article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

Targeted Augmentation of Nuclear Gene Output (TANGO) of SCN1A Reduces Seizures and Rescues Parvalbumin Positive Interneuron Firing Frequency in a Mouse Model of Dravet Syndrome. protein expression by leveraging the non-mutant (wild-type) copy of the SCN1A gene to restore physiological Na V 1.1 Translational Research / 2B.